webcast

Understanding MTX: How to Manage the Drug Informed by Science

PRESENTER: Joel Kremer, MD
PFAFF Family Professor of Medicine, Albany Medical College
Director of Research, The Center for Rheumatology
Chief Medical Officer, Corrona
Waltham, MD

Credits: 0.5

Release Date: May 13, 2019

Expiration Date: May 13, 2020

Target Audience:This activity has been designed to meet the educational needs of rheumatologists, physicians, physician assistants, and nurse practitioners involved in the care of patients with psoriatic disease.

Learning Objectives: After the completion of this activity, participants should be able to:

  • Describe how the biochemistry of methotrexate affects the clinical activity
  • Understand how to dose methotrexate
  • Determine how to recognize and treat methotrexate toxicities
  • STATEMENT OF SUPPORT: This activity is supported by educational grants from AbbVie, Amgen, Bristol-Myers Squibb, Janssen Biotech, Inc., Lilly, and Sandoz Inc., A Novartis Division

    PHYSICIAN ACCREDITATION STATEMENT: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Focus Medical Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

    CREDIT DESIGNATION: Purdue University College of Pharmacy designates this enduring activity for a maximum of
    0.5 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This program has been approved for 0.5 contact hours.

    DISCLOSURE STATEMENT: All faculty and staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

    All additional planning committee members, reviewers and Purdue University College of Pharmacy and Focus Medical Communications staff have no relationships to disclose.

    Joel Kremer, MD
    Dr. Kremer has received research support for clinical research on JAK inhibitors from AbbVie Inc., Lilly, and Pfizer. He has also been an advisor for AbbVie Inc., Gilead, Lilly, and Pfizer for research on JAK development.